Lurasidone combination therapy with fluvoxamine for OCD

Lurasidone combination therapy with fluvoxamine in moderate-to-severe obsessive-compulsive disorder: A placebo-controlled, double-blind, randomized trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20090117001556N169

Enrollment

Registered

2026-05-13

Start date

2026-05-01

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obsessive-compulsive disorder. Obsessive-compulsive disorder

Interventions

Intervention 1: Control group: patients will be treated with fluvoxamine 100 mg daily for the first four weeks and then 200 mg daily until the end of week 10 + placebo twice daily for 10 weeks. Interv

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Age between 18 to 60 years old Diagnosis of OCD (moderate to severe) based on DSM-5 Score of >21 in Yale–Brown obsessive-compulsive scale (Y-BOCS)

Exclusion criteria

Exclusion criteria: Presence of any underlying psychiatric disorder other than obsessive-compulsive disorder Taking an SSRI in the past 6 weeks Substance dependence Pregnant or breastfeeding women

Design outcomes

Primary

Measure	Time frame
Severity of OCD symptoms. Timepoint: Baseline and weeks 5 and 10. Method of measurement: By Yale–Brown obsessive-compulsive scale (Y-BOCS).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Shahin Akhondzadeh

Tehran University of Medical Sciences

s.akhond@sina.tums.ac.ir+98 21 5541 2222

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Jun 11, 2026